Study of PIVKA-II and AFP Measurement in Surveillance Program for Early Detection of Hepatocellular Carcinoma

Yonsei University

Status: Unknown

Conditions: Hepatocellular Carcinoma

Treatments: Device: tumor maker interval shortly

Study type: Observational

Funder types: Other

Identifiers

NCT01277653

AFP-PIVKA

Details and patient eligibility

About

There is no prospective study on the test intervals of alpha-fetoprotein (AFP) or on the role of prothrombin induced vitamin K absence or antagonist-II (PIVKA-II) in surveillance program for early detection of hepatocellular carcinoma(HCC). The goal of this study is to compare if the testing of AFP + PIVKA-II in intervals of 3 months is more effective in diagnosing early stages of HCC than the 6 month interval of AFP that is commonly used

Full description

There is no prospective study on the test intervals of alpha-fetoprotein (AFP) or on the role of prothrombin induced vitamin K absence or antagonist-II (PIVKA-II) in surveillance program for early detection of hepatocellular carcinoma(HCC). The goal of this study is to compare if the testing of AFP + PIVKA-II in intervals of 3 months is more effective in diagnosing early stages of HCC than the 6 month interval of AFP that is commonly used

Enrollment: 1,000 estimated patients

Sex: All

Ages: 20 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• LC

Exclusion criteria

• previous HCC

Trial design

1,000 participants in 2 patient groups

PIVKA-II and AFP 6 months

Description:

PIVKA-II and AFP measurement every 6 months

tumor maker interval every 6 month

Description:

tumor maker interval every 6 month

Treatment:

Device: tumor maker interval shortly